Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer

12 Feb 2022

Abstract excerpt

Treatment of locally advanced rectal cancer includes chemoradiation and surgery, but patient response to treatment is variable. Patients who have a complete response have improved outcomes; therefore, there is a critical need to identify mechanisms of resistance to circumvent them. DNA-PK is involved in the repair of DNA double-strand breaks caused by radiation, which we found to be increased in rectal cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Surgical Treatments
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35168148
DOI: 10.1016/j.neo.2022.01.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancerPMID 35168148Read ↗

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal CancerSemantic proximity Read ↗

Leveraging a Patient-Derived Tumoroid Platform for Precision Radiotherapy: Uncovering DNA Damage Repair Inhibitor-Mediated Radiosensitization and Therapeutic Resistance in Rectal CancerSemantic proximity Read ↗

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translationSemantic proximity Read ↗

New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapySemantic proximity Read ↗

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancerSemantic proximity Read ↗

PARP9-PARP13-PARP14 axis tunes colorectal cancer response to radiotherapySemantic proximity Read ↗

Inhibition of Non-Homologous End Joining Repair Impairs Pancreatic Cancer Growth and Enhances Radiation ResponseSemantic proximity Read ↗

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancerSemantic proximity Read ↗

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic StrategiesSemantic proximity Read ↗

Radiation Induced Checkpoint Immunotherapy Response in Refractory Colorectal and Pancreatic AdenocarcinomaSemantic proximity Read ↗

Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerSemantic proximity Read ↗

Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and ProtonsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.